I really don't want to be a doctor

Chapter 448
Tonight, for all the people in the tumor medicine circle, it is destined to be uneasy.

Fancheng Optics Valley.

The Shenzhou Laboratory, which was already in the dark, suddenly became lively.

Zhu Xianqing has notified all the researchers of the "Immune Checkpoint Inhibitor" project to return to the laboratory for a meeting urgently.

00:23 am

The huge laboratory is full of researchers.

Although Hong Sheng is not a member of the "Immune Checkpoint Inhibitor" project team, he also rushed to hear the news.

"Hey, Hong Sheng, you and Mr. Zhu are relatively close, do you know what happened? Why do you call all the people in the immune checkpoint inhibitor project team for an emergency meeting?"

Most of the researchers didn't know what happened, and they whispered to each other, trying to guess what happened.

It's late at night, and it's not the usual commute time, so everyone will inevitably complain.

At present, AstraZeneca has developed immune checkpoint inhibitors, only a few people in the circle know.

Hong Sheng shook his head and said, "I don't know either. I've been busy with the cardiac stem cell project and didn't pay much attention to it. Brother Awei, you're in the immune checkpoint inhibitor project team, do you know? "

Awei is a postgraduate student who graduated from Fancheng Medical University. After graduation, he came to Shenzhou Laboratory directly.

Awei frowned, "What I can touch is only a small part of the experiment, and the core part is in the hands of Mr. Zhu and a few others."

"Did you succeed in developing it?" The researcher next to him interrupted and asked.

Awei shook his head: "No, as far as I know, it should be a few weeks."

Hong Sheng was very puzzled. This was the first time he encountered such a situation since the establishment of the Shenzhou Laboratory.

Teacher Zhu Xianqing actually pulled everyone over for a meeting in the middle of the night, and Jing Xiaoran should also be there.

While everyone was guessing, Jing Xiaoran and Zhu Xianqing walked into the laboratory together.

The laboratory suddenly fell silent.

On the stage, Zhu Xianqing's expression was very serious, and everyone in the laboratory had a bad feeling in their hearts.

"Could it be..." Ah Wei in the audience was startled, thinking of a possibility.

"No, no." Awei shook his head feeling, driving this thought out of his mind.

At this time, Zhu Xianqing on the stage spoke in anticipation of everyone.

"Just now, 10 minutes ago, I received a message from the United States."

Speaking of this, Zhu Xianqing paused, looked around the laboratory, and then continued: "The American AstraZeneca laboratory announced that the immune checkpoint inhibitor they developed has officially entered the third phase of clinical trials."

The decibels of Zhu Xianqing's voice were very low, but as soon as the words came out, there was an uproar in the experiment.

In the audience, everyone looked shocked.

Especially the members of the "Immune Checkpoint Inhibitor" project team, each of them looked at Zhu Xianqing and Jing Xiaoran with disbelief.

Ah Wei clenched his hands tightly inside his cuffs, and his chest kept rising and falling.

He couldn't believe that his first project after graduation, a project he had been busy for half a year, was surpassed by other laboratories.

Jing Xiaoran imagined everyone's reaction.

Losing to AstraZeneca is impossible.

All experimental research is not achieved overnight.

Big companies such as AstraZeneca, Bayer, and Pfizer all have rich backgrounds, which are not comparable to their laboratory, which was established less than a year ago.

In other words, it is also unbelievable that Shenzhou Laboratory can almost catch up with AstraZeneca's experimental progress in a short period of time.

Among them, in addition to Jing Xiaoran's advanced experimental concepts, there are also researchers such as Zhu Xianqing, who worked hard day and night.

Although Hong Sheng is not an experimenter in the "immune checkpoint inhibitor" project team, he is very clear about what it means to let AstraZeneca take the lead?
They have seized this opportunity, and in the next few years, if there are no major accidents, the entire immune checkpoint inhibitor market will be firmly controlled by AstraZeneca.

They will be the first to complete Phase III clinical trials, be the first to market, and then occupy most of the global market
It is extremely difficult for Shenzhou Lab to get a share of it!
Even if it could, it would be leftovers.

But at this time, Jing Xiaoran on the stage smiled.

He looked at the crowd with sad faces, and the smile on his face did not diminish at all.

Ah Wei's heart trembled, the boss of his own laboratory must have been stimulated to be stupid, right?
At this time, can he still laugh?

In the lab, everyone had the same idea as Awei.

Why is my boss not sad but happy?

Apart from Hong Sheng, he knew Jing Xiaoran very well.

For so many years, no matter what Jing Xiaoran does, not to mention [-]% certainty, there is at least [-]% to [-]% hope.

"Perhaps, there may be a turning point..." Hong Sheng looked at Jing Xiaoran on the stage and muttered to himself.

In fact, when Jing Xiaoran just heard the news from Hammer from the United States, he was also very surprised.

During these days, he estimated the approximate completion time of these two laboratories by studying the recent literature on immune checkpoint inhibitors published by AstraZeneca and Bayer laboratories.

AstraZeneca should take about a month to officially enter the third phase of clinical trials, while Bayer needs at least one and a half months.

And Shenzhou Laboratory, if it increases its horsepower, can complete the research and development of all immune checkpoint inhibitors within half a month.

Even if there is an error, it will not be too bad.

But Jing Xiaoran did not expect that AstraZeneca directly advanced this time by one month.

Is there an error in his own estimation, or is there another reason?

Jing Xiaoran doesn't know, what he needs to face now is the consequences of failing the first stage of the scientific research competition.

Almost everyone's attention is on AstraZeneca's immune checkpoint inhibitor, and countless funds will continue to pour into it.

Once AstraZeneca's phase III clinical trial begins, it will be with an unstoppable trend, and it will become the first immune checkpoint inhibitor to be marketed with a high probability!
"The Long March has only taken the first step. Why do I feel that everyone seems to agree that our Shenzhou Laboratory has lost?"

Jing Xiaoran's voice sounded in the laboratory, and everyone felt very bitter when they heard the words.

Everyone understands the truth, but one step at a time, one step at a time!
What's more, the level of clinical trials in Europe and the United States is far superior to that in China. They took the lead in conducting the third phase of clinical trials, basically occupying the first place to go public.

Seeing that there was no response from the crowd, Jing Xiaoran continued, "Do you know when our Shenzhou laboratory started to conduct research on immune checkpoint inhibitors? Then when did laboratories such as AstraZeneca and Bayer start to develop where?"

(End of this chapter)